Alendronic acid
Articles · Medicine Compliance Aid Stability · Lactation Safety Information · Published , updated
421552005
Articles
20th February 2018
Can oral bisphosphonates be given to people with renal impairment to treat osteoporosis?
In the main, bisphosphonates are not metabolized and are excreted unchanged in urine. There are concerns about using them in chronic kidney disease, end-stage renal… Alendronic acid Endocrine system disorders Etidronate disodium Etidronic acid Ibandronic acid Medicine Musculo-skeletal disorders Pamidronate disodium Pamidronic acid Q&A Renal and urologic disorders Risedronate sodium Risedronic acid Sodium clodronate Zoledronic acid
13th October 2017
NICE Bites: Osteoporosis
Please go to NICE to check for any recent updates to this guideline. NICE Bites is a monthly prescribing bulletin published by North West Medicines… Alendronic acid Ibandronic acid Implementation Musculo-skeletal disorders News Primary Care Risedronate sodium Zoledronic acid
16th February 2017
Is there an interaction between bisphosphonates and proton pump inhibitors?
This updated Medicines Q&A evaluates the evidence for an interaction between bisphosphonates and proton pump inhibitors. Alendronic acid Esomeprazole Ibandronic acid Lansoprazole Omeprazole Pantoprazole Q&A Rabeprazole Risedronate sodium Zoledronic acid
4th September 2014
What are the risks of ocular adverse effects with bisphosphonate treatment?
There appears to be a link between bisphosphonate use and an increased risk of serious inflammatory ocular disorder such as uveitis and scleritis. The absolute… Alendronic acid Alendronic acid + Colecalciferol Eyes and vision Ibandronic acid Medicines Safety Q&A Risedronate sodium Risedronic acid
5th August 2014
What is the evidence for use of weekly alendronic acid in men?
Osteoporosis and fracture are a growing problem in the male population. Weekly doses of alendronic acid are not licensed in this group for either treatment… Alendronic acid Musculo-skeletal disorders Q&A
25th February 2014
Do gastric adverse events influence the choice of bisphosphonate for the treatment of osteoporosis?
This updated Medicines Q&A evaluates the published evidence examining the gastric safety of bisphosphonates for the treatment of osteoporosis. Alendronate should be the first choice… Alendronic acid Gastrointestinal disorders Ibandronic acid Musculo-skeletal disorders Q&A Risedronate sodium Risedronic acid
20th May 2012
Safety in Lactation: Drugs affecting bone metabolism
Drugs used exclusively for postmenopausal osteoporosis have not been included. Bisphosphonates have very poor oral bioavailability in fasting adults, which is decreased even further in… Alendronic acid Calcitonin Denosumab Etidronate disodium Ibandronic acid Pamidronate disodium Risedronate sodium Sodium clodronate
14th February 2008
RDTC Safer Medication Use – Bisphosphonates
Safer Medication Use is a new bulletin series developed with the Yellow Card Centre (Northern and Yorkshire). This issue highlights the safety aspects of oral… Alendronic acid Zoledronic acidMedicine Compliance Aid Stability
Fosamax · Merck Sharp & Dohme Ltd
Merck Sharp & Dohme Ltd
Fosamax
Tablets 10mg, 70mg
R2 · Red 2 · Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
No special precautions for storage. However complex administration regime makes it unsuitable for MCA.
19th February 2015
Lactation Safety Information
Sodium alendronate
Sodium alendronate
No published evidence of safety
Negligible levels anticipated in milk, due to drug’s properties, with subsequent minimal absorption from the infant’s GI tract